Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.59 |
| ▸ | GIPR | P48546 | 6/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254585 | 0.97 | GCGR (0.59) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL12360373 | 0.90 | GCGR (0.54) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL12360305 | 0.87 | GCGR (0.60) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL2252432 | 0.87 | GCGR (0.58) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL12360281 | 0.85 | GCGR (0.81) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL13755867 | 0.85 | GCGR (0.48) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL12360299 | 0.84 | GCGR (0.60) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL9071559 | 0.84 | GCGR (0.50) | GCGRGIPRHDAC1CYP3A4CYP2C8 | |
| SCHEMBL2251967 | 0.83 | GCGR (0.60) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL12360273 | 0.81 | GCGR (0.81) | GCGRGIPRHDAC1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989475-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1590336-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2009-08-27 | — | — | US | disclosed |
| US-7572922-B2 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2006-04-20 | — | — | US | disclosed |
| EP-1590336-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069158-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215825-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885HDAC1 1626/4885 |
| US-20060084681-A1 | Substituted pyrazoles, compositions containing such compounds and methods of use | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885HDAC1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.